EP3031811A1 — Malic acid esters of bortezomib
Assigned to Teva Pharmaceutical Industries Ltd · Expires 2016-06-15 · 10y expired
What this patent protects
Disclosed is a new chemical compound which is an ester formed between bortezomib and malic acid, wherein the ester can optionally be in the form of a pharmaceutically acceptable salt. Disclosed are further pharmaceutical compositions, preferably powders for solution for injection…
USPTO Abstract
Disclosed is a new chemical compound which is an ester formed between bortezomib and malic acid, wherein the ester can optionally be in the form of a pharmaceutically acceptable salt. Disclosed are further pharmaceutical compositions, preferably powders for solution for injection and solutions for injection containing the new ester compound or the pharmaceutically acceptable salts thereof as well as processes for preparing said pharmaceutical compositions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.